Bio-analytical testing services provider Eurofins Scientific has acquired the US prenatal screening laboratory services business PerkinElmer Labs/NTD.
The business, which was acquired from PerkinElmer, has initiated the research and development of prenatal screening protocols and provided the first biochemical screening test for early onset preeclampsia.
NTD’s trimester non-invasive prenatal screening test is claimed to be the only high sensitivity screen that uses the free Beta hCG biomarker, along with PAPP-A and Nuchal Translucency measurement, in evaluating risk for Down syndrome.
The acquired business will allow Eurofin to expand its presence in the genetics segment of the specialty clinical diagnostic testing market.
With around 80 employees, the NTD reported revenues of around $20m in last year.
PerkinElmer diagnostics president Prahlad Singh said: "Eurofins, with its breadth of testing services and capabilities, is uniquely positioned to meet the expanding service needs of NTD’s customers."
Eurofins CEO Dr Gilles Martin said: "NTD strengthens Eurofins’ testing capabilities for genetic disorders, and the Group’s footprint in the specialty clinical diagnostics market, with truly unique and innovative services with high positive impact for patient care."
PerkinElmer provides a range of diagnostic solutions, comprising of prenatal, neonatal and infectious disease screening and molecular diagnostics. It also offers various instruments, reagents and assay platforms, as well as software products.